why choose us

First received: October 13, 2023

Clinical Trial: ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: The Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin s Lymphoma

Brief Summary: Despite the progress in the therapy, Hodgkin's Lymphoma (HL) remains fatal for more than 15% of patients.Even in patients who are cured, the morbidity of therapy is substantial and long-lasting.New therapeutic agents are required therefore not only to further reduce mortality but also to alleviate morbidity.The majority of HL express the CD30 antigens.CD30 expression is routinely used for the diagnosis of HL.Preclinical observations support CD30 as a viable target of CAR-T therapy.This phase Ib/II study…

Read more